Pfizer (NYSE:PFE) Trading 0.9% Higher

Pfizer Inc. (NYSE:PFE) was up 0.9% during trading on Tuesday . The stock traded as high as $29.58 and last traded at $29.56. Approximately 5,411,390 shares were traded during trading, a decline of 86% from the average daily volume of 37,696,383 shares. The stock had previously closed at $29.31.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PFE shares. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, September 16th. UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Barclays increased their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

The company’s 50-day moving average is $29.36 and its two-hundred day moving average is $28.26. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a market cap of $166.43 billion, a P/E ratio of -492.58, a PEG ratio of 1.05 and a beta of 0.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $0.67 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.72%. Pfizer’s payout ratio is -2,799.53%.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently bought and sold shares of the stock. Olistico Wealth LLC bought a new stake in Pfizer during the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the second quarter valued at $29,000. Quarry LP purchased a new position in Pfizer during the 2nd quarter valued at $31,000. Creekmur Asset Management LLC bought a new position in Pfizer in the 4th quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its stake in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.